What is Cucurbitacin E (CuE) and where is it derived from?

Label:chem

Topic
Cucurbitacin E is a natural tetracyclic triterpenoid compound extracted from the melon stems of Cucurbitaceae plants such as cucumber, melon, watermelon, pumpkin, and squash.
Answer
Cucurbitacin E (CuE) is a bioactive triterpenoid isolated from Cucurbitaceae plants; it exhibits anti-inflammatory, anti-cancer, and immune-enhancing properties and is investigated here for its anti-adipogenic effects.
Return to Home Chemical List
Knowledge you may be interested in
Is the antiviral activity of zinc ions maintained across physiologically relevant temperatures? Does zinc-mediated inactivation compromise the structural integrity of the IAV particle? How do zinc ions affect influenza A virus (IAV) hemagglutinin function and virus infectivity? What role does desloratadine or levocetirizine play when added to oral isotretinoin in the treatment of acne vulgaris? What evidence supports the efficacy of relugolix combination therapy in endometriosis? How do clinical outcomes compare between relugolix monotherapy and combination therapy? Does relugolix combination therapy preserve BMD over extended treatment periods? What strategy has been developed to mitigate relugolix-induced BMD loss? How does relugolix monotherapy affect bone mineral density (BMD)? What is relugolix, and how does it function as a therapeutic agent in uterine diseases? Does Cucurbitacin E (CuE) exhibit cytotoxicity toward 3T3-L1 adipocytes during adipogenesis? How does CuE influence lipid accumulation in differentiating 3T3-L1 adipocytes? Which key adipogenic transcription factors are down-regulated by Cucurbitacin E (CuE)? What molecular pathways are implicated in CuE-mediated inhibition of adipogenesis and lipogenesis? What is the overall conclusion regarding CuE’s potential as an anti-obesity agent? What is the role of synthetic angiotensin II (Giapreza®/AT2S) in the peri-operative management of kidney transplantation? Were there any safety concerns specific to angiotensin II (Giapreza®/AT2S) use? What is nicotine's proposed mechanism of neuroprotection in Parkinson’s disease (PD)? What were the findings of the meta-analysis regarding nicotine's effect on motor symptoms in PD patients? Did nicotine therapy improve activities of daily living (ADLs), quality of life (QoL), or cognition in PD patients?